Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chitrananda Abeygunawardana

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Biologicals : Journal of the International Association of Biological Standardization|February 17, 2005
Alignment of absolute and relative molecular size specifications for a polyvalent pneumococcal polysaccharide vaccine (PNEUMOVAX 23)John E MacNair, Tejal Desai, Jennifer Teyral, et al.
Analytical Biochemistry|December 29, 2004
Characterization and quantification of C-polysaccharide in Streptococcus pneumoniae capsular polysaccharide preparationsQiuwei Xu, Chitrananda Abeygunawardana, Assunta S Ng, et al.
Analytical Biochemistry|February 5, 2005
Quantitative nuclear magnetic resonance analysis and characterization of the derivatized Haemophilus influenzae type b polysaccharide intermediate for PedvaxHIBQiuwei Xu, Jennifer Klees, Jennifer Teyral, et al.
Msphere|January 8, 2025
Establishing a new human pneumococcal standard reference serum, MPRSS-01Joseph M Antonello, Rocio D Murphy, Chitrananda Abeygunawardana, et al.
Vaccine|March 22, 2018
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of ageSusan J Ermlich, Charles P Andrews, Steven Folkerth, et al.
The Pediatric Infectious Disease Journal|November 15, 2019
Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human InfantsJinfu Xie, Yuhua Zhang, Ivette Caro-Aguilar, et al.
Human Vaccines & Immunotherapeutics|January 17, 2019
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adultsHelen L Stacey, Jeffrey Rosen, James T Peterson, et al.
Vaccine|September 25, 2018
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infantsDavid Greenberg, Patricia A Hoover, Timo Vesikari, et al.
Human Vaccines & Immunotherapeutics|May 21, 2021
Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and olderUlrike K Buchwald, Charles P Andrews, John Ervin, et al.
Carbohydrate Research|April 12, 2003
Isolation, structural characterization, and immunological evaluation of a high-molecular-weight exopolysaccharide from Staphylococcus aureusJoseph G Joyce, Chitrananda Abeygunawardana, Qiuwei Xu, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Biologicals : Journal of the International Association of Biological Standardization|February 17, 2005
Alignment of absolute and relative molecular size specifications for a polyvalent pneumococcal polysaccharide vaccine (PNEUMOVAX 23)John E MacNair, Tejal Desai, Jennifer Teyral, et al.
Analytical Biochemistry|December 29, 2004
Characterization and quantification of C-polysaccharide in Streptococcus pneumoniae capsular polysaccharide preparationsQiuwei Xu, Chitrananda Abeygunawardana, Assunta S Ng, et al.
Analytical Biochemistry|February 5, 2005
Quantitative nuclear magnetic resonance analysis and characterization of the derivatized Haemophilus influenzae type b polysaccharide intermediate for PedvaxHIBQiuwei Xu, Jennifer Klees, Jennifer Teyral, et al.
Msphere|January 8, 2025
Establishing a new human pneumococcal standard reference serum, MPRSS-01Joseph M Antonello, Rocio D Murphy, Chitrananda Abeygunawardana, et al.
Vaccine|March 22, 2018
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of ageSusan J Ermlich, Charles P Andrews, Steven Folkerth, et al.
The Pediatric Infectious Disease Journal|November 15, 2019
Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human InfantsJinfu Xie, Yuhua Zhang, Ivette Caro-Aguilar, et al.
Human Vaccines & Immunotherapeutics|January 17, 2019
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adultsHelen L Stacey, Jeffrey Rosen, James T Peterson, et al.
Vaccine|September 25, 2018
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infantsDavid Greenberg, Patricia A Hoover, Timo Vesikari, et al.
Human Vaccines & Immunotherapeutics|May 21, 2021
Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and olderUlrike K Buchwald, Charles P Andrews, John Ervin, et al.
Carbohydrate Research|April 12, 2003
Isolation, structural characterization, and immunological evaluation of a high-molecular-weight exopolysaccharide from Staphylococcus aureusJoseph G Joyce, Chitrananda Abeygunawardana, Qiuwei Xu, et al.
Pageof 1